Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Ningbo Menovo Pharmaceutical Co Days Payable?
Ningbo Menovo Pharmaceutical CoSHSE:603538 -9.99%55 Days Payable is 180.07 as of Mar. 2026, which is 6% above its 10-year median of 169.98. GuruFocus rates SHSE:603538 with a GF Score™ of 55/100 and a GF Value™ of ¥16.28 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 926 Drug Manufacturers companies, Ningbo Menovo Pharmaceutical Co ranks better than 84.67% on this metric.
The historical rank and industry rank for Ningbo Menovo Pharmaceutical Co's Days Payable or its related term are showing as below:
SHSE:603538'
s Days Payable Range Over the Past 10 Years
Min: 119.37 Med: 169.98 Max: 234.28
Current: 204.07
During the past 13 years, Ningbo Menovo Pharmaceutical Co's highest Days Payable was 234.28. The lowest was 119.37. And the median was 169.98.
SHSE:603538's Days Payable is ranked better than 84.67% of 926
companies
in the Drug Manufacturers industry
Industry Median: 90.455
vs SHSE:603538: 204.07
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ningbo Menovo Pharmaceutical Co Days Payable Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Ningbo Menovo Pharmaceutical Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ningbo Menovo Pharmaceutical Co Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Ningbo Menovo Pharmaceutical Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Ningbo Menovo Pharmaceutical Co's Days Payable falls into.
Ningbo Menovo Pharmaceutical Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ningbo Menovo Pharmaceutical Co (SHSE:603538) has a Days Payable of 180.07 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ningbo Menovo Pharmaceutical Co and its competitors. This is near median its historical median of 169.98. Over the past decade, Ningbo Menovo Pharmaceutical Co's Days Payable has ranged from 119.37 to 234.28. According to the industry distribution chart, Ningbo Menovo Pharmaceutical Co ranks #142 out of 926 companies in the Drug Manufacturers industry, placing it in the top 15.3%.
Is Ningbo Menovo Pharmaceutical Co's Days Payable too high?
Ningbo Menovo Pharmaceutical Co's current Days Payable of 180.07 is near median its 10-year median of 169.98. Over the past 10 years, this metric has ranged from a low of 119.37 to a high of 234.28. The Drug Manufacturers industry median Days Payable is 90.46. Ningbo Menovo Pharmaceutical Co's value of 180.07 is 99.1% above this industry median. Based on the distribution chart, Ningbo Menovo Pharmaceutical Co ranks #142 out of 926 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Ningbo Menovo Pharmaceutical Co has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ningbo Menovo Pharmaceutical Co's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Ningbo Menovo Pharmaceutical Co ranks #142 out of 926 companies for Days Payable. This places Ningbo Menovo Pharmaceutical Co in the top 15% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.46. Ningbo Menovo Pharmaceutical Co's value of 180.07 is 99.1% above this benchmark. Historically, Ningbo Menovo Pharmaceutical Co's own Days Payable has ranged from 119.37 to 234.28 over the past decade. While the company's 10-year median is 169.98 vs. the industry median of 90.46, Ningbo Menovo Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.46, based on 926 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ningbo Menovo Pharmaceutical Co's current Days Payable of 180.07 is 99.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Ningbo Menovo Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ningbo Menovo Pharmaceutical Co's current Days Payable is 180.07, which is near median its own 10-year median of 169.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ningbo Menovo Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Ningbo Menovo Pharmaceutical Co (SHSE:603538) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥16.28, compared to a current price of ¥34.52 — trading 112% above its estimated fair value. The current Days Payable is 180.07, which is near median its 10-year median of 169.98 and 99.1% above the Drug Manufacturers industry median of 90.46. Ningbo Menovo Pharmaceutical Co's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Ningbo Menovo Pharmaceutical Co (SHSE:603538), the current Days Payable is 180.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ningbo Menovo Pharmaceutical Co (SHSE:603538) Overvalued in 2026?
Based on GuruFocus' analysis, Ningbo Menovo Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥34.52 is trading 112% above its estimated GF Value™ of ¥16.28.
GuruFocus considers Ningbo Menovo Pharmaceutical Co to be Significantly Overvalued.
Key valuation signals for SHSE:603538:
Days Payable: 180.07 (near median its 10-year median of 169.98)
GF Value™: ¥16.28 vs. price of ¥34.52 (112% above fair value)
Industry Position: 99.1% above the Drug Manufacturers median (#142 of 926)
No single metric tells the full story. See the SHSE:603538 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ningbo Menovo Pharmaceutical Co Business Description
Ningbo Menovo Pharmaceutical Co Ltd is a China-based company is engaged in the research and development, pilot, production and sales of pharmaceutical intermediates, APIs and finished drugs. Its products line includes cardiovascular, central nervous, respiratory, anti-tumor, anti-infective, digestive system, geriatric diseases and anti-viral systems.
55GF Score
Get the complete analysis for SHSE:603538
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603538 has been successfully added to your 
